Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anaptysbio (ANAB) Liabilities and Shareholders Equity (2016 - 2025)

Anaptysbio (ANAB) has disclosed Liabilities and Shareholders Equity for 10 consecutive years, with $364.4 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Liabilities and Shareholders Equity fell 24.69% year-over-year to $364.4 million, compared with a TTM value of $1.5 billion through Dec 2025, down 18.54%, and an annual FY2025 reading of $364.4 million, down 24.69% over the prior year.
  • Liabilities and Shareholders Equity was $364.4 million for Q4 2025 at Anaptysbio, up from $353.1 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $643.1 million in Q4 2021 and bottomed at $335.2 million in Q2 2025.
  • Average Liabilities and Shareholders Equity over 5 years is $482.1 million, with a median of $468.1 million recorded in 2023.
  • The sharpest move saw Liabilities and Shareholders Equity skyrocketed 57.7% in 2022, then decreased 28.44% in 2025.
  • Year by year, Liabilities and Shareholders Equity stood at $643.1 million in 2021, then dropped by 5.08% to $610.4 million in 2022, then decreased by 25.88% to $452.4 million in 2023, then rose by 6.95% to $483.8 million in 2024, then fell by 24.69% to $364.4 million in 2025.
  • Business Quant data shows Liabilities and Shareholders Equity for ANAB at $364.4 million in Q4 2025, $353.1 million in Q3 2025, and $335.2 million in Q2 2025.